WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Saved in:

Bibliographic Details
Main Authors:	María José Soler Romeo, Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, Mónica Bolufer, Clara García-Carro, Mario Sánchez, Carla Alonso-Martínez, Pere Barba, Ander Vergara Arana
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492400247X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Proceedings of sessions of the Pirogov Surgical Societies № 2513
by: Article Editorial
Published: (2018-12-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
by: Sigrun Einarsdottir, et al.
Published: (2025-07-01)

Advances in Chimeric Antigen Receptor T-cell therapy for hematologic malignancies and autoimmune conditions: a review of the 2024 American Society of Hematology Annual Meeting
by: Samuel Davis, et al.
Published: (2025-06-01)

Lean Mass Longitudinally Confounds Sedentary Time and Physical Activity With Blood Pressure Progression in 2513 Children
by: Andrew O. Agbaje
Published: (2024-12-01)

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
by: Hannah Karlsson, et al.
Published: (2015-01-01)

Advance in chimeric antigen receptor T therapy in autoimmune diseases
by: Xiaolan Ji, et al.
Published: (2025-03-01)

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
by: Sudjit Luanpitpong, et al.
Published: (2021-01-01)

Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
by: Zhenpo Zhang, et al.
Published: (2025-05-01)

The potential of chimeric antigen receptor -T cell therapy for endocrine cancer
by: Ruonan Yu, et al.
Published: (2025-04-01)

Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy
by: Jia-Hui Liu, et al.
Published: (2025-05-01)

Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters
by: Hyung Bae Park, et al.
Published: (2024-11-01)

Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles
by: Keyu Li, et al.
Published: (2017-03-01)

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation
by: Shaomei Feng, et al.
Published: (2025-06-01)

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
by: C. Carcopino, et al.
Published: (2024-12-01)

Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T‐Cell Therapy
by: Jia Yi Tan, et al.
Published: (2025-03-01)

Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs
by: Guo-Fen Re, et al.
Published: (2022-10-01)

Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells
by: Alvin Man Lung Chan, et al.
Published: (2025-07-01)

Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy
by: Yong Liu, et al.
Published: (2025-07-01)

MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma
by: Fenghao Zhang, et al.
Published: (2025-04-01)

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
by: Mingwei Jiang, et al.
Published: (2025-12-01)

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
by: Cynthia J. Siebrand, et al.
Published: (2025-05-01)

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01)

Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors
by: A. А. Pavlova, et al.
Published: (2017-04-01)

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods
by: Bo Zou, et al.
Published: (2024-03-01)

Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer
by: Lvying Wu, et al.
Published: (2025-04-01)

Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia
by: Yang Liu, et al.
Published: (2025-05-01)

Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy
by: Rui Gu, et al.
Published: (2025-01-01)

Modelling protein-protein interactions for the design of vaccine chimeric antigens with protective epitopes.
by: Marinela Contreras, et al.
Published: (2025-01-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy
by: Lu Wang, et al.
Published: (2025-04-01)

Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults
by: Víctor Galán-Gómez, et al.
Published: (2025-04-01)

Target selection and clinical chimeric antigen receptor T cell activity against solid tumors
by: Eric vonHofe, et al.
Published: (2023-06-01)

Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico
by: Rosario Salazar-Riojas, et al.
Published: (2025-04-01)

Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
by: Le Qin, et al.
Published: (2025-02-01)

Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology
by: Shuochao Ji, et al.
Published: (2025-04-01)

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)